University of Virginia Patent Foundation;UNIVERSITAT DE BARCELONA;Consejo Superior de Investigaciones Cientificas
发明人:
Thomas P. Loughran, JR.,Gemma Fabrias,Jose Luis Abad,Josefina Casas,David J. Feith,Su-Fern Tan,Jennifer M. Pearson,Antonio Delgado Cirilo
申请号：
US16609124
公开号：
US20200276138A1
申请日:
2018.04.27
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present application provides novel compositions and methods for treating acute myeloid leukemia (AML). Compounds of the invention are acid ceramidase inhibitors, reduce AML cell viability, inhibit AML cell proliferation, increase cell death of AML cells, and induce apoptosis in AML cells. A primary compound of the invention is SACLAC: 2-chloro-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide. The bromine analog of SACLAC (SABRAC: 2-bromo-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide) is also useful for treating AML. SACLAC has much better activity than other know drugs used to treat AML.
